Physician profile
Jean E Wilson
NPI 1700866266
$2,399.79
in general payments reported to CMS, 2019-2025
29 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $291 · 2021: $506 · 2022: $339 · 2023: $218 · 2024: $237 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $368.77 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $252.74 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $228.06 | 2019-2024 | Xarelto |
| Kiniksa Pharmaceuticals, LTD. | $180.38 | 2021-2023 | Arcalyst |
| Amarin Pharma, INC. | $178.94 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $108.28 | 2019-2020 | |
| Novo Nordisk INC | $106.38 | 2020-2025 | Wegovy, Saxenda |
| Kiniksa Pharmaceuticals International, Plc | $98.44 | 2024 | Arcalyst |
| Pfizer INC. | $96.28 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $86.85 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $78.78 | 2020-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.16 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $60.26 | 2021-2025 | Capvaxive, Verquvo |
| E.R. Squibb & Sons, L.L.C. | $56.63 | 2021-2024 | Camzyos |
| Lilly USA, LLC | $52.97 | 2024-2025 | Mounjaro, Zepbound |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $46.20 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $45.67 | 2021 | |
| Abbott Laboratories | $45.60 | 2021-2023 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $42.43 | 2019-2025 | Evkeeza |
| Glaxosmithkline, LLC. | $31.42 | 2021 | |
| Medtronic, INC. | $24.77 | 2025 | Venaseal |
| Inspire Medical Systems, INC. | $23.61 | 2025 | Inspire |
| Exact Sciences Corporation | $21.89 | 2025 | The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $18.37 | 2023 | Accrufer |
| Hikma Pharmaceuticals USA | $17.34 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.81 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $13.94 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.00 | 2020 | |
| Esperion Therapeutics, INC. | $11.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.